Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$615.69 USD
-6.08 (-0.98%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $615.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Thermo Fisher Scientific (TMO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$629.39 | $670.00 | $565.00 | 1.23% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Thermo Fisher Scientific comes to $629.39. The forecasts range from a low of $565.00 to a high of $670.00. The average price target represents an increase of 1.23% from the last closing price of $621.77.
Analyst Price Targets (18)
Broker Rating
Thermo Fisher Scientific currently has an average brokerage recommendation (ABR) of 1.52 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.52 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 13 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 65% and 15% of all recommendations. A month ago, Strong Buy made up 65%, while Buy represented 15%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TMO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 12 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 4 | 4 | 4 | 4 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.52 | 1.52 | 1.52 | 1.52 | 1.63 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/25/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
7/25/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
7/25/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
7/16/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
7/2/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
6/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/18/2024 | Not Identified | Not Identified | Strong Buy | Hold |
1/8/2024 | Not Identified | Not Identified | Strong Buy | Hold |
10/27/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.52 |
ABR (Last week) | 1.52 |
# of Recs in ABR | 20 |
Average Target Price | $629.39 |
LT Growth Rate | 9.90% |
Industry | Medical - Instruments |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | 5.29 |